Insmed Stock Slides — CFO Exit Date Set, 2026 Guidance Reaffirmed
Insmed Inc. (NASDAQ: INSM ) shares are trading lower by almost 7% on Monday as traders digest a CFO transition update alongside a slightly softer risk tone. Insmed CFO Transition and 2026 Guidance Reaffirmed Insmed said CFO Sara Bonstein will step down on October 30 after nearly seven years in the role, while the company reaffirmed its full-year 2026 financial guidance. "We are now well positioned to reach cash flow positivity next year with what we view as a clear path toward sustained top-line growth and bottom-line profitability," said Will Lewis, Chair and CEO of Insmed. Insmed reaffirms its full-year 2026 financial guidance of revenue in the range of $1.25 billion to $1.40 billion for BRINSUPRI (brensocatib) and $450 million to $470 million for ARIKAYCE (amikacin liposome inhalation suspension). In September, the U.S. Food and Drug Administration (FDA) accepted Insmed’s supplemental application for ARIKAYCE for Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen. The FDA granted Priority Review and set a target action date of January 28, 2027. Read Also: Insmed Sees Sustained Gains With Inhaled Drug for Stressed Heart Functioning
Insmed Inc. (NASDAQ: INSM ) shares are trading lower by almost 7% on Monday as traders digest a CFO transition update alongside a slightly softer risk tone. Insmed CFO Transition and 2026 Guidance Reaffirmed Insmed said CFO Sara Bonstein will step down on October 30 after nearly seven years in the role, while the company reaffirmed its full-year 2026 financial guidance. "We are now well positioned to reach cash flow positivity next year with what we view as a clear path toward sustained top-line growth and bottom-line profitability," said Will Lewis, Chair and CEO of Insmed.
40 billion for BRINSUPRI (brensocatib) and $450 million to $470 million for ARIKAYCE (amikacin liposome inhalation suspension). S. Food and Drug Administration (FDA) accepted Insmed’s supplemental application for ARIKAYCE for Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen. The FDA granted Priority Review and set a target action date of January 28, 2027.
82), which keeps rallies vulnerable to selling pressure. 89), suggesting the market hasn’t reclaimed the intermediate trend. The death cross that formed in April (50-day SMA below the 200-day SMA) remains an overhang for longer-term trend followers, even though the 20-day SMA is still above the 50-day SMA (a shorter-term bullish crossover). 00 — a nearby level where buyers previously stepped in, close to the current price zone INSM Earnings Preview And Wall Street Analyst Targets Looking further out, the next major catalyst for the stock arrives with the October 29, 2026 (estimated) earnings report.
40. 61 at the time of publication on Monday, according to Pro data. Photo: Shutterstock Read Also: Cardano Surges 11% While Bitcoin, Ethereum, XRP Barely Move